CNP520
Total Payments
$38.5M
Transactions
710
Doctors
64
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $2.4M | 90 | 0 |
| 2019 | $29.4M | 110 | 0 |
| 2018 | $6.2M | 105 | 1 |
| 2017 | $432,154 | 405 | 63 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $38.4M | 362 | 99.9% |
| Travel and Lodging | $30,708 | 157 | 0.1% |
| Food and Beverage | $20,845 | 190 | 0.1% |
| Consulting Fee | $400.00 | 1 | 0.0% |
Payments by Type
Research
$38.4M
362 transactions
General
$51,953
348 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY OF TWO DOSES OF CNP520 IN PARTICIPANTS AT RISK FOR THE ONSET OF CLINICAL SYMPTOMS OF AD | Novartis Pharmaceuticals Corporation | $37.4M | 0 |
| A 5 YEAR PROSPECTIVE STUDY OF AN ANTI AMYLOID THERAPY CAD106 OR CNP520 IN SLOWING AND OR POSTPONING COGNITIVE DECLINE IN ASYMPTOMATIC APOE 4 HOMOZYGOTES AT RISK FOR DEVELOPING ALZHEIMERS DISEASE DEMENTIA | Novartis Pharmaceuticals Corporation | $564,911 | 0 |
| PROSPECTIVE OBSERVATIONAL COHORT STUDY ON NATURAL DISEASE PROGRESSION AND BURDEN ACROSS THE ENTIRE ALZHEIMER?S SPECTRUM (IMAP STUDY) | Novartis Pharmaceuticals Corporation | $291,131 | 0 |
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY OF TWO DOSES OF CNP520 IN PARTICIPANTS AT RISK FOR THE ONSET OF CLINICAL SYMPTOMS OF AD | NOVARTIS PHARMACEUTICALS CORPORATION | $137,779 | 0 |
Top Doctors Receiving Payments for CNP520 — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Neurology | Philadelphia, PA | $601.29 | 3 |
| , MD | Specialist | Pittsburgh, PA | $583.66 | 5 |
| , M.D | Psychiatry | Oklahoma City, OK | $580.91 | 2 |
| , MD | Neurology with Special Qualifications in Child Neurology | Tallahassee, FL | $580.91 | 2 |
| Ralph Richter | — | Tulsa, OK | $532.61 | 4 |
| , M.D | Geriatric Psychiatry | Austin, TX | $503.90 | 3 |
| , MD | Neurology | Lexington, KY | $467.66 | 3 |
| , MD | Neurology | Palm Beach Gardens, FL | $465.92 | 1 |
| , MD | Neurology | St Paul, MN | $429.55 | 5 |
| , MD PHD | Anesthesiology | Boston, MA | $400.00 | 1 |
| , M.D | Neurology | Houston, TX | $391.66 | 3 |
| , M.D | Neurology | Jacksonville, FL | $371.67 | 3 |
| , M.D | Psychiatry | San Juan, PR | $363.43 | 4 |
| , MD | Neurology | Palo Alto, CA | $347.95 | 2 |
| , MD | Neurology | Providence, RI | $180.63 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $38.5M
- Total Doctors 64
- Transactions 710
About CNP520
CNP520 is a drug associated with $38.5M in payments to 64 healthcare providers, recorded across 710 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $2.4M was paid across 90 transactions to 0 doctors.
The most common payment nature for CNP520 is "Unspecified" ($38.4M, 99.9% of total).
CNP520 is associated with 4 research studies, including "A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY OF TWO DOSES OF CNP520 IN PARTICIPANTS AT RISK FOR THE ONSET OF CLINICAL SYMPTOMS OF AD" ($37.4M).